ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alexion cuts 20% and moves to Boston

by Ryan Cross
September 18, 2017 | APPEARED IN VOLUME 95, ISSUE 37

Rare-disease drugmaker Alexion Pharmaceuticals will cut 20% of its workforce, about 600 jobs, and move its headquarters to Boston, leaving about 450 positions behind in New Haven, Conn. The move comes amid controversy over aggressive sales practices for Alexion’s drug Soliris, which treats rare blood diseases, that led to the ousting of its CEO. The downsizing includes the shuttering of a plant in Smithfield, R.I., and the end of partnerships with Moderna Therapeutics and Arbutus Biopharma.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment